Recent Updates
Recently added Catalysts
ANRO Positive Sentiment

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Thursday, August 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alto Neuroscience has announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. In his new role, Smith will lead the finance function and oversee corporate strategy and business development. This move is part of the company's efforts to enhance its leadership as it develops novel treatments for neuropsychiatric disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nick Smith's promotion highlights his contributions to the company.
  • Alto Neuroscience continues to strengthen its leadership team.
  • The company is focused on developing precision medicines for neuropsychiatric disorders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+393%
120-day peak, hindsight
Typical move
43.3%
average across 2 past catalysts
Cash runway
~37 mo
Low dilution risk
Lead asset
ALTO-101
Phase 2 · Schizophrenia

Full Press Release Details

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead Alto’s finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto’s founder, chief executive officer and c

Frequently Asked Questions

Who was promoted at Alto Neuroscience?

Nick Smith was promoted to president and chief financial officer.

When does Nick Smith's promotion take effect?

His promotion is effective August 26, 2026.

What will Nick Smith oversee at Alto Neuroscience?

He will lead the finance function and oversee corporate strategy.

Who does Nick Smith report to?

He reports to Amit Etkin, the CEO and founder of Alto Neuroscience.

ShareAdd on Google
Tags: ANRO Viatris Investor Conferences Healthcare Alto Neuroscience Nick Smith CFO neuropsychiatric disorders clinical-stage biopharmaceutical
Last updated: Aug 27, 2026

Biotech snapshot

Cash runway
$244M liquidity · $7M/mo burn
~37 mo
Low dilution risk
Lead asset
ALTO-101Phase 2
Schizophrenia →

Catalyst track record

+393%
best trade around ANRO's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ANRO.

See every catalyst's timing & PoA →